Vistagen Therapeutics Inc (NAS:VTGN)

Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript

Feb 13, 2025 / 10:00 PM GMT

Release Date Price: $2.85 (+4.01%)

Transcript 10-Q8-K

Key Points

Positve

Vistagen Therapeutics Inc (VTGN) reported positive results from their Palisade 2 Phase 3 trial for the acute treatment of social anxiety disorder (SAD) with their lead product candidate, fasinol.
The company has initiated Palisade 3 and Palisade 4 Phase 3 trials, which are advancing towards expected top-line results later this year.
Vistagen is exploring additional applications for their product candidates, including Iruone for major depressive disorder and PH80 for menopausal hot flashes.
The company has a diverse pipeline with five clinical-stage intranasal product candidates, all showing positive efficacy signals and differentiated safety profiles.
Vistagen has a strong cash position with $88.6 million in cash equivalents and marketable securities as of December 31, 2024, providing financial stability for ongoing research and development.

Negative

Research and development expenses increased significantly to $11.3 million for the quarter, up from $4.5 million in the same period last year, indicating higher costs associated with advancing their clinical programs.
General and administrative expenses also rose to $4.0 million, compared to $33.8 million last year, primarily due to increased headcount.
The net loss attributable to common stockholders was $14.1 million for the quarter, compared to $6.4 million in the same period last year, reflecting increased operational costs.
There is potential competition in the market for novel drugs targeting social anxiety disorder, which could impact Vistagen's market position.
The company faces regulatory risks, particularly if the repeat dose study of fasinol shows that two doses are more efficacious than one, which could complicate the approval process.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VTGN.OQ - VistaGen Therapeutics Inc
Q3 2025 Vistagen Therapeutics Inc Earnings Call
Feb 13, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day.

Thank you for standing by. Welcome to this genre's 3rd quarter fiscal year 2025 corporated conference call. At this time, all participants are on the listen-only mode.

After the speaker's presentation, there will be a question and answer session. So as a question during the session, you will need to press 11 on your telephone. You will then hear an automatic message advising your hand is raised. Please note that today's conference is being recorded.

I will now hand a conference over to your speaker host, Mark McPartland, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.